Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States.
It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy.
Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 24 | 0.00 Increased by +100.00% | -0.32 Increased by +100.00% |
| Mar 21, 24 | -0.42 Decreased by -90.91% | -0.35 Decreased by -20.00% |
| Nov 9, 23 | -0.37 Decreased by -54.17% | -0.31 Decreased by -19.35% |
| Aug 10, 23 | -0.31 Decreased by -24.00% | -0.20 Decreased by -55.00% |
| May 10, 23 | -0.40 Decreased by -81.82% | -0.34 Decreased by -17.65% |
| Mar 22, 23 | -0.22 Increased by +62.07% | -0.29 Increased by +25.42% |
| Nov 9, 22 | -0.24 Increased by +47.83% | -0.25 Increased by +4.00% |
| Aug 11, 22 | -0.25 Decreased by -308.33% | -0.25 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.87 M Decreased by -60.49% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -5.01 M Decreased by -26.38% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -5.95 M Decreased by -73.58% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -3.21 M Decreased by -3.67% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -3.66 M Decreased by -153.71% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -3.97 M Increased by +21.17% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -3.43 M Decreased by -284.27% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -3.09 M Decreased by -293.99% | Decreased by N/A% Decreased by N/A% |